Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
85
-
Total 13F shares, excl. options
-
45.2M
-
Shares change
-
-8.28M
-
Total reported value, excl. options
-
$82.7M
-
Value change
-
-$18.5M
-
Put/Call ratio
-
0
-
Number of buys
-
42
-
Number of sells
-
-64
-
Price
-
$1.83
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q2 2022
129 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q2 2022.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 85 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45.2M shares
of 166M outstanding shares and own 27.33% of the company stock.
Largest 10 shareholders include BVF INC/IL (5.8M shares), VANGUARD GROUP INC (5.08M shares), RTW INVESTMENTS, LP (2.85M shares), Point72 Asset Management, L.P. (2.75M shares), Rubric Capital Management LP (2.41M shares), ORBIMED ADVISORS LLC (2.12M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2M shares), ACADIAN ASSET MANAGEMENT LLC (1.84M shares), BlackRock Inc. (1.83M shares), and Candriam S.C.A. (1.65M shares).
This table shows the top 85 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.